Introduction
Treatment for CML has changed dramatically after the emergence of tyrosine kinase inhibitors (TKIs), and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is occasionally performed in CML patients after disease progression to AP or blastic phase. Additional chromosomal aberrations including double Ph, +8, i(17q), and +19 are frequently observed in CML. These aberrations are categorized as major routes that reflect cytogenetic clonal evolution [1] . Wang et al. analyzed the aberrations in CML patients treated with TKIs and showed that better response was observed in a group with +8, −Y, and double Ph compared to another group with i(17)(q10), −7/ del(7q), and 3q26.2 rearrangements [2] . The former group with favorable aberrations showed equivalent responses to TKIs as those observed in CML patients without additional aberrations. Notably, in addition to these two groups, 47 % of CML patients show other single aberrations. Mortality after allo-HSCT is much higher than that after treatment with TKIs. Furthermore, a portion of CML patients is able to discontinue TKIs treatment. Thus, cases of Ph-positive CML with additional translocations at diagnosis require precise evaluation of cytogenetic analysis, especially in the TKIs era.
Reciprocal chromosomal translocations, such as t(8;21) (q22;q22) and t(15;17)(q22;q21) are well-known causes of leukemia and malignant lymphoma. These translocations are also reported to be rarely observed in CML. This is the first report of a Ph-positive CML patient with a constitutional t(8;22)(q24;q11.2) chromosomal translocation. As Abstract Constitutional translocations that coincide with t(9;22)(q34;q11.2) may lead to unnecessary treatments in chronic myeloid leukemia (CML) patients, as, under the standard criteria, a diagnosis of CML with additional chromosomal abnormalities indicates an accelerated phase (AP). In the present report, a 47-year-old male had pain in the right foot due to gout. Peripheral blood examination showed leukocytosis with left shift. Bone marrow aspiration revealed myeloid hyperplasia with megakaryocytosis. RT-PCR revealed the major BCR-ABL fusion transcript, and CML in the chronic phase was diagnosed, followed by nilotinib treatment. Although WBC counts decreased immediately, G-banding analysis showed 46,XY,t(8;22)(q24;q11.2),t(9;22)(q34;q11.2) [20] . The t(8;22)(q24;q11.2) translocation is known to be recurrent in Burkitt's lymphoma. The diagnosis was changed to CML in AP, leading to B-lymphoid crisis. Unexpectedly, the karyotype was 46,XY,t(8;22)(q24;q11.2) [20] in hematological complete remission, even after 3 months. Fluorescence in situ hybridization on metaphase spreads revealed the MYC signal on the der(22)t (8;22) , indicating that the 8q24 breakpoint was centromeric to MYC at 8q24.21. G-banding analysis of phytohemagglutinin-stimulated peripheral blood T-lymphocytes also indicated 46,XY,t(8;22)(q24.1;q11.2). We conclude that the t(8;22) is constitutional in this patient. As the tumor suppressor gene TRC8/RNF139 is disrupted by constitutional t(8;22)(q24.13;q11.21) in dysgerminoma, it may be associated with the onset of CML. t(8;22)(q24;q11.2) is involved in the pathogenesis of Burkitt's lymphoma, the coincidence of these reciprocal translocations resulted in confusion regarding the disease status as being in B-lymphoid crisis at initial diagnosis.
Case report
A 47-year-old male with pain in the right foot due to gout and leukocytosis was referred to the Kobe University Hospital. The patient had no history of disease or intellectual deterioration. Peripheral blood examination showed leukocytosis with a left shift (WBC 20 × 10 9 /L, myelocytes 4 %, metamyelocytes 13 %, stab cells 2 %, segmented cells 58 %, eosinophils 4 %, basophils 4 %, monocytes 7 %, and lymphocytes 8 %). The hemoglobin level was 15.4 g/dl and the platelet count was 353 × 10 9 /L. CML was suspected owing to the increased number of basophils, and bone marrow aspiration was performed. The bone marrow was hypercellular; the number of megakaryocytes was increased and the ratios of the cells were as follows: blasts 0.6 %, promyelocytes 2.4 %, myelocytes 11.4 %, metamyelocytes 19.4 %, stab cells 20.8 %, segmented cells 27.4 %, eosinophils 3.6 %, basophils 1 %, monocytes 0.4 %, lymphocytes 1.8 %, and plasma cells 0.4 %. The major BCR-ABL transcript was detected at >626 copies/assay using the TMA method, and FISH analysis revealed the BCR-ABL fusion signal in 96 % of the bone marrow cells (Fig. 1a) . From these results, CML in CP was diagnosed, and treatment was initiated immediately with a TKI, nilotinib, at a dosage of 600 mg daily. The WBC count decreased to 10.4 × 10 9 and 5.7 × 10 9 /L at 1 week and 2 weeks after nilotinib administration, respectively. However, the BCR-ABL transcript was still detected at >626 copies/assay even after 1 month. Moreover, cytogenetic analysis revealed an abnormal karyotype, 46,XY,t(8;22)(q24;q11.2),t(9;22)(q34;q11.2) [20] (Fig. 2a) . The clinical stage of the patient was reconsidered as AP leading to B-lymphoid crisis, because it is not Fig. 1 FISH analyses of [20] (Fig. 2b) , whereas the major BCR-ABL transcript was barely detected under the measurable limit by real-time PCR. Moreover, metaphase FISH revealed the MYC signal on der(22) t(8;22), indicating that the 8q24 breakpoint was centromeric to MYC at 8q24.21 (Fig. 1b) . That is, t(8;22)(q24;q11.2) in the present case was different from that observed in Burkitt's lymphoma. At this point, we speculated that t(8;22) (q24;q11.2) was a constitutional chromosomal translocation in this patient. Indeed, further chromosomal analysis using phytohemagglutinin (PHA)-stimulated peripheral blood T-lymphocytes also showed the identical chromosomal translocation as follows: 46,XY,t(8;22)(q24.1;q11.2) [20] (Fig. 2c) . Treatment with nilotinib, without allo-HSCT, was continued afterwards, and complete molecular response was maintained for at least 18 months after the initial diagnosis.
Discussion
Constitutional translocations that coincide with Ph-positive CML have been reported, most being Robertsonian translocations, including t(13;14)(q10;q10), t(14;15)(q10;q10), and t(15:22)(q10;q10) [3] [4] [5] [6] [7] . On the other hand, non-Robertsonian translocations are rarely observed in Ph-positive CML [8] .
The chromosomal translocation t(8;22)(q24;q11.2) in Burkitt's lymphoma juxtaposes the MYC oncogene at 8q24 to the immunoglobulin light chain gene (IGL) at 22q11.2. The 8q24 breakpoints in t(8;22)(q24;q11.2) in Burkitt's lymphoma are observed to be within 300 kb of the MYC 3′ UTR [9] . Because the t(8;22)(q24;q11.2) translocation detected in the present case was initially thought to be an additional translocation in CML, the patient was suspected to be in an accelerated phase leading to B-lymphoid crisis. However, FISH DNA probes designed against the flanking MYC 3′ UTR breakpoint on 8q24.2 loci did not detect a split signal. Moreover, the cytogenetic study of PHA-stimulated peripheral blood lymphocytes only showed the chromosomal translocation t(8;22)(q24.1;q11.2). These results indicate that t(8;22)(q24;q11.2), in the present case, is a constitutional change, and t(8;22)(q24;q11.2) was, indeed, found to persist after TKI treatment in our case, whereas t(9;22)(q34;q11.2) was lost.
Apart from hematological diseases, four recurrent constitutional non-Robertsonian translocations including t(11;22)(q23;q11), t(4;8)(p16;p23), t(8;22)(q24.13;q11.21), and t(9;22)(q34;q11.2), have been reported so far [10] [11] [12] [13] [14] . Among these, the presence of t (8;22) and t(9;22) definitely lead to confusion in diagnosis when the patients show abnormal findings in blood or physical examinations as in the present case, mainly because these translocations are frequently detected in hematological malignancies.
Constitutional t(8;22)(q24;q11.2) is occasionally found in females who are phenotypically normal carriers after the birth of intellectually deteriorated offspring. The wife of the male carrier experiences recurrent spontaneous abortions. Using PCR analysis of sperm DNA, Sheridan et al. demonstrated that t(8;22) occurs during gametogenesis in some healthy individuals [10] . In this case, we advised the patient and his daughter to undergo genetic counseling, because carriers are at risk of bearing progeny with the supernumerary der(22)t(8;22) syndrome as a result of abnormally segregated der (22) . This translocation is also observed in patients with abnormal hematological findings including leukocytosis and thrombocytosis [15] .
Thus, the 22q11.2 locus is a hot spot for non-random chromosomal aberrations that result in deletion, supernumerary chromosomes, and interstitial duplications. The lesions on chromosome 22 that are responsible for these rearrangements were identified in low copy repeats (LCRs). There are eight LCRs (A to H) on chromosome 22 and these LCRs show 97-98 % sequence homology to each other [16, 17] . Gotter et al. confirmed that the low copy repeat B on 22q11.2 is involved in t(8;22)(q24.13;q11.21) [18] .
In contrast, the breakpoints on chromosome 8 in the t(8;22)(q24.13;q11.2) reciprocal constitutional translocation are identified in palindromic AT-rich repeats (PATRR) that are placed proximal to MYC [19] . Gimelli et al. demonstrated that the tumor suppressor gene, TRC8/RNF139, on chromosome 8 is disrupted by t(8;22)(q24.13;q11.21) in a patient with dysgerminoma and suspected it as the cause for disease onset [20] . Moreover, the authors demonstrated the interaction of TRC8/RNF139 with COPS5/JAB1, a subunit of the COP-9 signalosome, as well as with VHL [21] . Jab1 binds to p27
Kip1 and the binding results in the degradation of p27
Kip1 [22] . Therefore, the disruption of TRC8/ RNF139 by t (8;22) would allow the interaction between Jab1 and p27 Kip1 leading to the reduction of p27 Kip1 , which phenomenon is reported to induce genetic instability [23] . Intriguingly, t(3;8)(p14;q24.1) observed in renal cell carcinoma, also involves this 8q breakpoint region [24, 25] . Therefore, it is possible that hematologic disorders with these constitutional translocations will result from the dysfunction of this tumor suppressor gene.
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